




Amendments to the Claims


This listing of claims will replace all prior versions and listing of claims in this application:

1. (Allowed) A water-soluble drug-polymer conjugate selected from a conjugate of formula I, II, III, IV and V:






,





, AND



wherein

R¹ is alkyl, a drug-polymer conjugate of formula (A) or a drug-polymer conjugate of formula (B):





R^2 is -O-, -NH-, or -S-;

R^3 is alkyl, a cycloalkyl, or aryl;

R^4 is H, =O, -O-COC₄H₉, or OR⁷;

R^6 is =O or OR⁷;

R^7 is H, COR⁹ or alkyl;

R^8 is alkyl or H;


R^9 is alkyl, H, aryl, or -CH₂Ar; and

n is 1-1000.

2. (Allowed) A pharmaceutical composition comprising the water-soluble drug-polymer conjugate of claim 1 and a pharmaceutically acceptable carrier.


3.-13. (Cancelled)

14. (Allowed) A water-soluble drug-polymer conjugate having the structure of formula I



wherein:

R^1 is alkyl, or a drug-polymer conjugate of formula (A)



R^2 is -O-, -NH-, or -S-;

R^3 is alkyl, a cycloalkyl, or aryl;

R^6 is =O or OR^7 ;

R^7 is H, COR^9 or alkyl;

R⁸ is alkyl or H;

R⁹ is alkyl, H, aryl, or -CH₂Ar; and

n is 1-1000.

15. (Allowed) The water-soluble drug-polymer conjugate of claim 14 wherein n is 250 – 400.

16. (Allowed) The water-soluble drug-polymer conjugate of claim 14 wherein n is 50 – 150.

17. (Allowed) The water-soluble drug-polymer conjugate of claim 14 wherein the molecular weight of polymer is from about 400 to about 80,000.


18. (Allowed) The water-soluble drug-polymer conjugate of claim 14 wherein the molecular weight of polymer from about 1000 to about 8000.

19. (Allowed) The water-soluble drug-polymer conjugate of claim 14 wherein the molecular weight of polymer is from about 4000 to about 6000.

20. (Allowed) A pharmaceutical composition comprising the water-soluble drug-polymer conjugate of claim 14 and a pharmaceutically acceptable carrier.


21.-31. (Cancelled)

32. (Allowed) A water-soluble drug-polymer conjugate having the structure of formula I:



wherein:

R¹ is alkyl, or a drug-polymer conjugate of formula (B)



R² is -O-, -NH-, or -S-;

R³ is alkyl, a cycloalkyl, or aryl;

R⁴ is H, =O, -O-COC₄H₉, or OR⁷;

R⁷ is H, COR⁹ or alkyl;

R⁸ is alkyl or H;

R⁹ is alkyl, H, aryl, or -CH₂Ar; and

n is 1-1000.

33. (Allowed) The water-soluble drug-polymer conjugate of claim 32 wherein n is 250 – 400.

34. (Allowed) The water-soluble drug-polymer conjugate of claim 32 wherein n is 50 – 150.

35. (Allowed) The water-soluble drug-polymer conjugate of claim 32 wherein the molecular weight of polymer is from about 400 to about 80,000.


36. (Allowed) The water-soluble drug-polymer conjugate of claim 32 wherein the molecular weight of polymer is from about 1000 to about 8000.

37. (Allowed) The water-soluble drug-polymer conjugate of claim 32 wherein the molecular weight of polymer is from about 4000 to about 6000.

38. (Allowed) A pharmaceutical composition comprising the water-soluble drug-polymer conjugate of claim 32 and a pharmaceutically acceptable carrier.


39.-49. (Cancelled)

50. (Allowed) A water-soluble drug-polymer conjugate having the structure of formula II



wherein:

R¹ is alkyl, or a drug-polymer conjugate of formula (B)



R² is -O-, -NH-, or -S-;

R³ is alkyl, a cycloalkyl, or aryl;

R⁴ is H, =O, -O-COC₄H₉, or OR⁷;

R⁷ is H, COR⁹ or alkyl;

R⁸ is alkyl or H;

R⁹ is alkyl, H, aryl, or -CH₂Ar; and

n is 1-1000.

51. (Allowed) The water-soluble drug-polymer conjugate of claim 50 wherein n is 250 – 400.

52. (Allowed) The water-soluble drug-polymer conjugate of claim 50 wherein n is 50 – 150.

53. (Allowed) The water-soluble drug-polymer conjugate of claim 50 wherein the molecular weight of polymer is from about 400 to about 80,000.


54. (Allowed) The water-soluble drug-polymer conjugate of claim 50 wherein the molecular weight of polymer is from about 1000 to about 8000.

55. (Allowed) The water-soluble drug-polymer conjugate of claim 50 wherein the molecular weight of polymer is from about 4000 to about 6000.

56. (Allowed) A pharmaceutical composition comprising the water-soluble drug-polymer conjugate of claim 50 and a pharmaceutically acceptable carrier.

57.-67. (Cancelled)

68. (Allowed) A water-soluble drug-polymer conjugate having the structure of formula III:



n is 1-1000.

69. (Allowed) The water-soluble drug-polymer conjugate of claim 68 wherein n is 250-400.


70. (Allowed) The water-soluble drug-polymer conjugate of claim 68 wherein n is 50-150.

71. (Allowed) The water-soluble drug-polymer conjugate of claim 68 wherein the molecular weight of polymer is from about 400 to about 80,000.

72. (Allowed) The water-soluble drug-polymer conjugate of claim 68 wherein the molecular weight of polymer is from about 1000 to about 8000.

73. (Allowed) The water-soluble drug-polymer conjugate of claim 68 wherein the molecular weight of polymer is from about 4000 to about 6000.

74. (Allowed) A water-soluble drug-polymer conjugate having the structure of formula IV:



wherein $n = 1-1000$.

75. (Allowed) The water-soluble drug-polymer conjugate of claim 74 wherein n is 250 – 400.

76. (Allowed) The water-soluble drug-polymer conjugate of claim 74 wherein n is 50 – 150.

77. (Allowed) The water-soluble drug-polymer conjugate of claim 74 wherein the molecular weight of polymer is from about 400 to about 80,000.

78. (Allowed) The water-soluble drug-polymer conjugate of claim 74 wherein the molecular weight of polymer is from about 1000 to about 8000.

79. (Allowed) The water-soluble drug-polymer conjugate of claim 74 wherein the molecular weight of polymer is from about 4000 to about 6000.


80. (Allowed) A pharmaceutical composition comprising the water-soluble drug-polymer conjugate of claim 74 and a pharmaceutically acceptable carrier.

81.-91. (Cancelled)

92. (Allowed) A process for the preparation of a water-soluble drug-polymer conjugate of claim 68 comprising:


- a. adding a solvent to 17-dihydro-17-(1-iodoacetyl)-wortmannin to obtain a solution;
- b. adding a tertiary amine or sodium bicarbonate to the solution;
- c. adding mPEG-sulfhydryl 5000 to the solution of step (b);
- d. stirring the solution of step (c) for 30 minutes;
- e. adding ether to the stirred solution;
- f. collecting the solid; and
- g. washing the collected solid with ether to obtain the pegylated wortmannin derivative.

93. (Allowed) A water-soluble drug-polymer conjugate having the structure of formula V:



wherein:

R^1 is alkyl, or a drug-polymer conjugate of a single non-repeating formula (V)



R^2 is -O-, -NH-, or -S-;

R^3 is alkyl, a cycloalkyl, or aryl;

R^4 is H, =O, -O-COC₄H₉, or OR⁷;


R^7 is H, COR^9 or alkyl;

R^8 is alkyl or H;

R^9 is alkyl, H, aryl, or $-CH_2Ar$; and


n is 1-1000.

94. (Allowed, Currently Amended) A process for the preparation of the compound of claim 93 comprising addition of an amine to a compound of claim 50 having the structure of formula II



wherein:

R^1 is alkyl, or a drug-polymer conjugate of formula (B)



R² is -O-, -NH-, or -S-;

R³ is alkyl, a cycloalkyl, or aryl;

R⁴ is H, =O, -O-COC₄H₉, or OR⁷;

R⁷ is H, COR⁹ or alkyl;

R⁸ is alkyl or H;

R⁹ is alkyl, H, aryl, or -CH₂Ar; and

n is 1-1000;

to obtain a compound of claim 93.

95. (Allowed) A process of claim 94 wherein the amine comprises diethyl amine.

96. (Allowed) A process for the preparation of a water-soluble drug-polymer conjugate of claim 74 comprising:

- a) adding a solvent to 11-desacetyl-11-(1-iodoacetyl)-wortmannin to obtain a solution;
- b) adding a tertiary amine to the solution;
- c) adding mPEG-sulfhydryl 5000 to the solution of step (b);

- d) stirring the solution of step (c) for 30 minutes;
- e) adding ether to the stirred solution;
- f) collecting the solid; and
- g) washing the collected solid with ether to obtain the pegylated wortmannin derivative, as disclosed.